Waiting for new drugs for rare disorders in Canada – part 1, regulatory approval: Nigel Rawson and John Adams for Inside Policy
This article is the first in an 8-part series from the authors. The series, Waiting for new drugs for ...
Tag: John Adams
For drug access, Canadians with rare disorders are 40 years behind Americans: Nigel Rawson and John Adams in the Financial Post
This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, January 24, 2023 Forty years ago ...
PMPRB continues plan to drive down drug prices as patients suffer: Nigel Rawson and John Adams for Inside Policy
By Nigel Rawson and John Adams, November 23, 2022 For seven years, the Patented Medicines Prices Review Board (PMPRB) – ...
Suffer from a rare disorder in Canada? Good luck: Nigel Rawson and John Adams in the Financial Post
This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, November 2, 2022 This month marks ...
Ottawa should reset its relationship with drug developers to improve patient health: Rawson and Adams for Inside Policy
By Nigel Rawson and John Adams, May 2, 2022 On April 14, 2022, Health Minister Jean-Yves Duclos announced the federal ...
‘Big Tobacco’ COVID-19 vaccine: What were the Liberals thinking? Nigel Rawson and John Adams in the Financial Post
This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, April 22, 2022 After being late to ...
The Macdonald-Laurier Institute Welcomes Newest Senior Fellows, Nigel Rawson and John Adams
OTTAWA, ON (April 11, 2022): We are pleased to announce that Nigel Rawson and John Adams will be joining the ...
Timely access for patients to innovative medicines – A policy change overdue: Rawson and Adams for Inside Policy
By Nigel Rawson and John Adams, March 24, 2022 Much has been written over the last few years about the ...
Canadians will pay a heavy price as Ottawa cuts drug costs
A new MLI commentary warns that pending and aggressive drug price control efforts could lead to major unintended consequences in ...
False Premise – Federal Regulation of Drug Prices as a Step to National Pharmacare: Rawson and Adams in National Newswatch
Advocates for national pharmacare who insist on control of drug prices, not by negotiation but by federal regulation, may have ...
Appeal court exposes PMPRB abuse of power and bias on drug pricing: Nigel Rawson and John Adams in the Financial Post
The Appeal Court’s unanimous decision demonstrates that the Patented Medicine Prices Review Board is out of control in an anti-industry, ...
New Federal Regulations to Reduce Drug Prices Will Only Hinder Innovation: New MLI Paper by Nigel Rawson and John Adams
OTTAWA, ON (June 3, 2021): The COVID-19 pandemic has unmasked a dangerous lack of investment in pharmaceutical and vaccine research, development, and ...
-
Quebec’s dairy farmers are blocking free trade in Canada: Stuart J. Smyth for Reason
-
How much did Canada’s trade retaliation and boycotts actually hurt the U.S.? Trevor Tombe in The Hub
-
‘Far too serious for such uninformed, careless journalism’: MLI’s Mia Hughes pens formal complaint challenging Globe article on gender medicine
-
Crisis of Conformity: The urgent need to restore open inquiry and free expression in Canada’s universities
-
University of Toronto education project risks reinforcing Russian disinformation: Marcus Kolga in the National Post
